In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "outlook," "guidance," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.
All statements other than statements of historical facts are forward-looking statements, including statements regarding our first ever transplant of a bioengineered liver transplant into a large animal. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
For more information, visit .Ĭautionary Statement Regarding Forward-Looking Statements The Company's initial development focus is on human livers and kidneys. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. Miromatrix's perfusion decellularization and recellularization technology platform includes 119 issued and 34 pending patent applications, with protection in the United States and major markets worldwide. "This important patent demonstrates our ability to revascularize decellularized organs and furthers our commitment to bioengineering completely functional, transplantable organs to solve this major health crisis." "Organ transplantation is one of the largest unmet medical needs facing the world today," says Miromatrix CEO Jeff Ross, Ph.D.
Patent Number 11,414,644 is entitled "Methods of Recellularizing a Tissue or Organ for Improved Transplantability." This patent covers the revascularization of decellularized organs and tissues that encompasses all types of organs including liver, lung, kidney, and heart. This new patent further expands the Company's extensive patent portfolio covering the bioengineering of transplantable organs. ( MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, has received a new patent from the United States Patent and Trademark Office for its perfusion decellularization and recellularization technology. 25, 2022 (GLOBE NEWSWIRE) - Miromatrix Medical Inc. Motorola Moto G22 has been launched in India which comes with an iPhone-like flat edge design and a protruding rear camera module.EDEN PRAIRIE, Minn., Aug. Motorola has launched one more budget smartphone for the Indian market. Motorola Moto G22 launched in India with Helio G37 SoC & quad-camera setup.The device is meant for budget consumers and does not come with 5G connec… Moto G52 has been launched which was earlier launched in the European market. Motorola has launched its next in the G Series in India. Motorola Moto G52 goes official in India: Read on to know more.Motorola Moto G52 review summary: Editor rating: 3.5/5 Design Display Performance Battery Camera Pros Large battery life Fast charging Clean UI IP52 Rating Decent 50MP camera Cons Poor gaming performance slip… Motorola Moto G52 Review: Budget-Friendly smartphone to meet all your needs?.It is a simple process since you don’t have to do any rocke… If you have a credit card and want to use its prowess via UPI, you can give thanks as long as you are paying to a Bharat QR Code-supported merchant. How To Pay UPI Through Credit Card On Google Pay, PhonePe, & Paytm.MMS, Instant Messaging, Voice Commands, Calendar, YouTube Player Spot Color, Night Vision, Cinemagraph, Portrait w/ HDR, Cutout, Live Filter, Panorama, Ultra-Res, AR Stickers, Pro ModeĨ MP f/2.4 (Ultra Wide) with Screen Flashġx3.2 GHz Kryo 585 & 3x2.42 GHz Kryo 585 & 4x1.80 GHz Kryo 585 Yes, with dual-band AGPS, LTEPP, SUPL, GLONASS, Galileoįace detection, Smile detection, Geo tagging, Panorama, Touch to focus
0 kommentar(er)
